Evidence map›Paper›PMID 40677145›Full record

ArticleDiabetes, obesity & metabolism2025

Neurobeachin (NBEA) is a novel gene associated with GLP-1 receptor agonist associated weight loss.

Arshiya Mariam-Smith, Joseph H Breeyear, Noah J Daniels, Kevin M Pantalone, Marcio L Griebeler, Alison A Motsinger-Reif, Daniel M Rotroff

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Arshiya Mariam-SmithDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0003-4427-0275
Joseph H BreeyearBiostatistics and Computational Biology Branch, Division of Intramural Research, National Institute of Environmental Health Sciences, Durham, North Carolina, USA.
Noah J DanielsDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Kevin M PantaloneCenter for Quantitative Metabolic Research, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0002-3897-4551
Marcio L GriebelerCenter for Quantitative Metabolic Research, Cleveland Clinic, Cleveland, Ohio, USA.
Alison A Motsinger-ReifBiostatistics and Computational Biology Branch, Division of Intramural Research, National Institute of Environmental Health Sciences, Durham, North Carolina, USA.
Daniel M RotroffDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0003-0553-3220

Funding

Center for Quantitative Metabolic Research, Cleveland Clinic
6 · The paper itself

Abstract

aimsNearly 42% of adults in the United States have obesity, a significant risk factor for many cardiometabolic diseases and cancers. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are promising interventions for weight loss, but their efficacy varies significantly across individuals. This study investigates the role of neurobeachin (NBEA), a gene that encodes a protein kinase A anchor protein, on weight loss response in two large, real-world cohorts. MATERIALS AND

methodsWe utilised data from individuals prescribed a GLP-1RA in the NIH All of Us (N = 6556) and validated in the UK Biobank (N = 241). The NBEA genetic score for weight loss (12-18 months) was developed using the NIH All of Us cohort and independently validated in the UK Biobank. Logistic regression modelled associations between the score and outcomes, including high responsiveness (top 20th percentile for weight loss) and non-responsiveness (weight change ≥0%).

resultsIndividuals meeting the responsive NBEA score threshold were 82% more likely to be highly responsive (FDR p = 1·8 × 10

conclusionThese findings indicate that NBEA genetic variation is predictive of GLP-1RA weight loss and may support future efforts to identify individuals likely to experience significant weight loss with GLP-1RAs, enabling personalised obesity treatment strategies.

Indexed as

Adaptor Proteins, Signal TransducingGlucagon-Like Peptide-1 Receptor AgonistsNerve Tissue ProteinsObesityWeight LossAdultAgedCohort StudiesFemaleHumansLiraglutideMaleMiddle AgedUnited KingdomAdaptor Proteins, Signal TransducingGlucagon-Like Peptide-1 Receptor AgonistsLiraglutideNerve Tissue Proteinselectronic health recordsgenetic scoreGLP‐1RANBEAweight loss

Identifiers

PMID40677145
PMCPMC12409233

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.